From Pharmacogenetics to Personalized Medicine: A vital Need for Educating Health Professionals and the Community
- 1 July 2004
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 5 (5) , 571-579
- https://doi.org/10.1517/14622416.5.5.571
Abstract
The field of pharmacogenetics will soon celebrate its 50th anniversary. Although science has delivered an impressive amount of information in these 50 years, pharmacogenetics has suffered from lack of integration into clinical practice. There are several reasons for this, including the unmet need for education at medical schools and the lack of awareness about the impact of genetic medicine on healthcare in the community. Recently, the FDA announced that it considers pharmacogenomics one of three major opportunities on the critical path to new medical products. This notion by the FDA is filling the regulatory void that existed between drug developers and drug users. However, in order to bring pharmacogenetic testing to the prescription pad successfully, healthcare professionals and policy makers, as well as patients, need to have the necessary background knowledge for making educated treatment decisions. To effectively move pharmacogenetics into everyday medicine, it is therefore imperative for scientists and teachers in the field to take on the challenge of disseminating pharmacogenetic insights to a broader audience.Keywords
This publication has 63 references indexed in Scilit:
- Personalized psychiatry: a realistic goalPharmacogenomics, 2004
- Polymorphic sequence variants in medicine: a challenge and an opportunityClinical Medicine, 2003
- Pharmacology and Physiology of Human Adrenergic Receptor polymorphismsAnnual Review of Pharmacology and Toxicology, 2003
- Polymorphisms of the β2-Adrenergic ReceptorNew England Journal of Medicine, 2002
- Gene–environment interactions—the BioBank UK studyThe Pharmacogenomics Journal, 2002
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotypeJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency, Thalassaemia, and Abnormal Haemoglobins in the PhilippinesJournal of Medical Genetics, 1964